Skip to main content

Oral Contraceptive Pills : Uses , Fuctions, Toxic Syndrommes..........



















Oral cotraceptive pills are tablets that prevents conception. Perhaps its the most accepted contraceptive method in developing countries. Its principle function is to prevent conception and it doesn't give any protection against HIV and other STD's.


Oral Contraceptive Pills (OCP) are mainly two types.

1. Combiled OCP.
2. Progesteron OR Estrogen only Pills.

The mechanism of action of OCP is very simple. We know that female Menstrual cycle is devided into three phases.

1. Proliferative phase : Here estrogen is secreted by Ovary , which causes uterine endrometrial growth. After this phase there is sudden withdrwal af estrogen which causes Ovulation ( It is the fall of mature ovum into Peritoneal Cavity , which ultimately comes into the uterine tube and finally in uterus ).

2. Secretory phase : Here both Progesterone and Estrogen Causes more and more growth if endometrium and increase secretion by the uterine glands.

3. The Menstrual phase : Here sudden Withdrawal of Progesterone cause increase uterine contraction and shedding out of uterine endometrium with mature Ovum , which is visible as bleeding.






















Now, OCP maintains a steady concentration of estrogen and progesterone into the body. Though , Ovulation occur due to sudden withdrawal of estrogen and OCP maintains estrogen level , so , there is no ovulation in the body. And , there is menstruation due to sudden withdrawal of progesterone , because , OCP intake should be stopped after 21 days. After this , the women will take 7 Iron tablets , and by this period there is sudden withdrwal of progesterone in the body. So , there is menstruation but without any ovulation.
Now, though there is no ovulation so , so Sperms inters into the vagina and uterus they can not find any mature ovum in female genital tract. So , there is no fertilization in the body. So, that women will not conceve .
By this way OCP maintains Contraception into the body.












Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibody Targets, Kills Leukemia Cells

Monoclonal Antibody Targets, Kills Leukemia Cells  Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells. Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell death.
1 comment
Read more

Stem Cell Treatment May Become Option to Treat Nonhealing Bone Fractures

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston. A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill. "This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible" Fractures that do not hea
Post a Comment
Read more

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with
Post a Comment
Read more